A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)


Kayikcioglu M., Tokgozoglu L., YILMAZ M., KAYNAR L., Aktan M., Durmus R. B. , ...More

ATHEROSCLEROSIS, vol.270, pp.42-48, 2018 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 270
  • Publication Date: 2018
  • Doi Number: 10.1016/j.atherosclerosis.2018.01.034
  • Journal Name: ATHEROSCLEROSIS
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.42-48

Abstract

Background and aims: Homozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by lethally high levels of low-density lipoprotein cholesterol (LDL-C) from birth, and requires rapid and aggressive intervention to prevent death due to coronary heart disease and/or atherosclerosis. Where available, lipoprotein apheresis (LA) is the mainstay of treatment to promote survival.